No Data
No Data
Tasly Pharmaceutical Group's (600535.SH) subsidiary, Carter's oral solution of bupropion hydrochloride, has obtained a pharmaceutical registration certificate.
Tasly Pharmaceutical Group (600535.SH) announced that its wholly-owned subsidiary, Jiangsu Tasly Diyi Pharmaceutical Co., Ltd., ...
Tasly Pharmaceutical Group Co., Ltd Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Tasly Pharmaceutical Group 2024 Semi-Annual Report
Summary of Tasly Pharmaceutical Group's 2024 semi-annual report
Tasly Pharmaceutical Group (600535.SH): The net income in the first half of the year was 0.662 billion yuan, a 6.33% decrease year-on-year, with a proposed dividend of 2.6 yuan.
GeLongHui August 23 | Tasly Pharmaceutical Group (600535.SH) announced its interim report for the first half of 2024, with revenue of 4.372 billion yuan, a decrease of 0.46% year-on-year; net income attributable to shareholders of the listed company was 0.662 billion yuan, a decrease of 6.33% year-on-year; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.735 billion yuan, an increase of 6.31% year-on-year; basic earnings per share was 0.4433 yuan. It is proposed to distribute a cash dividend of 2.6 yuan (tax included) for every 10 shares to all shareholders. The revenue decreased by 0.46% compared to the same period last year, with pharmaceutical industry revenue increasing by 4.
Private Companies Are Tasly Pharmaceutical Group Co., Ltd's (SHSE:600535) Biggest Owners and Were Hit After Market Cap Dropped CN¥1.2b
No Data
No Data